Welcome to our dedicated page for Sangamo Therapeutics news (Ticker: SGMO), a resource for investors and traders seeking the latest updates and insights on Sangamo Therapeutics stock.
Sangamo Therapeutics Inc (NASDAQ: SGMO) is a clinical-stage biopharmaceutical leader pioneering genomic medicines through innovative gene editing and gene therapy approaches. This dedicated news hub provides investors and researchers with timely updates on the company's scientific advancements, regulatory milestones, and therapeutic developments.
Access authoritative updates including press releases on clinical trial progress, partnership announcements with biotech leaders, and research breakthroughs in neurology, hemophilia, and rare genetic disorders. Our curated collection ensures you stay informed about SGMO's pipeline developments, including zinc finger protein therapies and in vivo genome editing applications.
Key content categories feature earnings reports, FDA regulatory updates, scientific publication highlights, and strategic collaboration news. Bookmark this page for direct access to primary source materials from Sangamo Therapeutics, maintaining your awareness of critical developments in precision genomic medicine.
Sangamo Therapeutics (SGMO) announced updated results from the Phase 1/2 STAAR study of isaralgagene civaparvovec (ST-920) for treating Fabry disease. As of February 14, 2022, the therapy showed general tolerability with no serious adverse events. Five patients exhibited sustained elevated α-Gal A activity levels, ranging from 3 to 17 times above normal for up to 15 months. The study has advanced to the dose expansion phase, and additional patients, including four who discontinued enzyme replacement therapy (ERT), have been dosed, with results expected later in 2022.
Sangamo Therapeutics (Nasdaq: SGMO) reported second quarter 2022 results, highlighting significant advances in its clinical programs. The company is progressing with its TX200 program for renal transplant rejection, now with Orphan Medicinal Product Designation from the European Commission. Revenues increased to $29.4 million, with a net loss of $43.2 million, an improvement from a net loss of $47.2 million in 2021. Total operating expenses decreased slightly to $75.1 million. The company maintains its financial guidance for total operating expenses for 2022.
Sangamo Therapeutics (NASDAQ: SGMO) has announced the release of its second quarter 2022 financial results, scheduled for August 4, 2022, after market close. A conference call to discuss these results will take place at 4:30 p.m. ET, open to the public. Participants are encouraged to register and join the call 10 minutes early for seamless access. A replay of the call will be available under the company's Events and Presentations section on its website, providing investors with insights into the company's financial performance and business developments.
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) announced that the European Commission has granted Orphan Medicinal Product Designation to TX200, a CAR-Treg therapy for solid organ transplantation. This designation aims to reduce transplant rejection and the burden of lifelong immunosuppressive therapy. The STEADFAST Phase 1/2 clinical study has already dosed the first patient in March 2022, with further dosing planned. TX200 is designed to prevent immune rejection in mismatched kidney transplants by promoting immunological tolerance, offering 10 years of market exclusivity upon approval.
Sangamo Therapeutics (Nasdaq: SGMO) announced its participation in key investor conferences in June and July 2022. The company will present at the Jefferies Healthcare Conference on June 9 at 9:00 a.m. ET and the Guggenheim I&I Spotlight Series focused on Treg-based therapies on July 12 at 2:45 p.m. ET. Access to presentations will be available on the company's website. Sangamo Therapeutics specializes in genomic medicines, utilizing innovative zinc finger technology to address treatment gaps for patients.
Sangamo Therapeutics (Nasdaq: SGMO) reported significant advancements in its clinical programs during Q1 2022, including the first patient dosed in a kidney transplant rejection study using CAR-Treg therapy. With a net loss of $44.0 million, or $0.30 per share, the company saw a revenue increase to $28.2 million, attributed to collaborations with Novartis, Biogen, and Sanofi. The company maintains an outlook for total operating expenses between $320 million and $350 million for 2022, with a cash position of $400.3 million as of March 31, 2022, ensuring continued operational support.
Sangamo Therapeutics (NASDAQ: SGMO) announced acceptance of eight abstracts for presentation at the 25th ASGCT Annual Meeting, taking place May 16-19, 2022, in Washington, D.C. Presentations will highlight advancements in Sangamo's genomic engineering platform, including a study on AAV capsids for CNS delivery, which address challenges posed by the blood-brain barrier. Notable studies include presentations on base-editing and CAR-T cell engineering. Sangamo aims to showcase its innovative research, contributing to transformative medicine for patients with unmet needs.
Sangamo Therapeutics (NASDAQ: SGMO) announced the release of its first quarter 2022 financial results, scheduled for May 5, 2022, after market close. A conference call will be held at 4:30 p.m. ET to discuss the results and provide business updates, accessible via telephone and webcast. Domestic callers can dial (877) 377-7553, while international participants may call (678) 894-3968, using conference ID 3090098. A replay will be available for one week following the event. For more information, visit the Sangamo Therapeutics website.
Sangamo Therapeutics (Nasdaq: SGMO) announced participation in three upcoming investor conferences. The events are:
- Bank of America Securities Conference on May 11 at 3:00 p.m. ET
- RBC Global Healthcare Conference on May 18 at 3:05 p.m. ET
- H.C. Wainwright Global Investment Conference on May 24 at 7:00 a.m. ET
Access to presentations will be available on the Sangamo Therapeutics website under the Investors and Media section.
Sangamo Therapeutics (SGMO) announced the dosing of the first patient in its Phase 1/2 STEADFAST clinical study for TX200, an innovative CAR-Treg cell therapy aimed at preventing immune-mediated rejection in HLA-A2 mismatched kidney transplants. This represents a significant milestone in genomic medicine, with hopes of reducing the need for lifelong immunosuppressants. The study aims to assess TX200's safety and effectiveness, marking a potential breakthrough in treating patients receiving kidneys from living donors.
FAQ
What is the current stock price of Sangamo Therapeutics (SGMO)?
What is the market cap of Sangamo Therapeutics (SGMO)?
